An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).
A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.
A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.
Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones.
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.
An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.
A bile salt formed in the liver by conjugation of chenodeoxycholate with taurine, usually as the sodium salt. It acts as detergent to solubilize fats in the small intestine and is itself absorbed. It is used as a cholagogue and choleretic.
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).
Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).
The 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholanic acid family of bile acids in man, usually conjugated with glycine or taurine. They act as detergents to solubilize fats for intestinal absorption, are reabsorbed by the small intestine, and are used as cholagogues and choleretics.
A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.
A semisynthetic bile acid made from cholic acid. It is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid.
Unstable isotopes of selenium that decay or disintegrate emitting radiation. Se atoms with atomic weights 70-73, 75, 79, 81, and 83-85 are radioactive selenium isotopes.
Operation for biliary atresia by anastomosis of the bile ducts into the jejunum or duodenum.
A bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic.
A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES.
A bile pigment that is a degradation product of HEME.
The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed.
A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic.
Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions.
A conditionally essential nutrient, important during mammalian development. It is present in milk but is isolated mostly from ox bile and strongly conjugates bile acids.
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.
Radiography of the gallbladder after ingestion of a contrast medium.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.
Progressive destruction or the absence of all or part of the extrahepatic BILE DUCTS, resulting in the complete obstruction of BILE flow. Usually, biliary atresia is found in infants and accounts for one third of the neonatal cholestatic JAUNDICE.
The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.
Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin.
Inorganic and organic derivatives of sulfuric acid (H2SO4). The salts and esters of sulfuric acid are known as SULFATES and SULFURIC ACID ESTERS respectively.
A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.
Enzymes of the oxidoreductase class that catalyze the dehydrogenation of hydroxysteroids. (From Enzyme Nomenclature, 1992) EC 1.1.-.
The BILE DUCTS and the GALLBLADDER.
An acid-base indicator which is colorless in acid solution, but turns pink to red as the solution becomes alkaline. It is used medicinally as a cathartic.
An autosomal recessive lipid storage disorder due to mutation of the gene CYP27A1 encoding a CHOLESTANETRIOL 26-MONOOXYGENASE. It is characterized by large deposits of CHOLESTEROL and CHOLESTANOL in various tissues resulting in xanthomatous swelling of tendons, early CATARACT, and progressive neurological symptoms.
A genus of gram-positive, rod-shaped bacteria found in cavities of man and animals, animal and plant products, infections of soft tissue, and soil. Some species may be pathogenic. No endospores are produced. The genus Eubacterium should not be confused with EUBACTERIA, one of the three domains of life.
Minute intercellular channels that occur between liver cells and carry bile towards interlobar bile ducts. Also called bile capillaries.
A storage reservoir for BILE secretion. Gallbladder allows the delivery of bile acids at a high concentration and in a controlled manner, via the CYSTIC DUCT to the DUODENUM, for degradation of dietary lipid.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Published materials which provide an examination of recent or current literature. Review articles can cover a wide range of subject matter at various levels of completeness and comprehensiveness based on analyses of literature that may include research findings. The review may reflect the state of the art. It also includes reviews as a literary form.
Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.
The transference of a part of or an entire liver from one human or animal to another.

Primary biliary cirrhosis associated with membranous glomerulonephritis. (1/432)

A 33-year-old woman was admitted to our department for evaluation of liver dysfunction and proteinuria. A liver biopsy specimen showed ductular proliferation and moderate portal fibrosis indicating stage II primary biliary cirrhosis. A renal biopsy specimen showed mild to moderate mesangial cell proliferation without crescent formation or interstitial nephritis. Immunofluorescent staining revealed deposition of immunoglobulin G (IgG), third component of complement (C3), and Clq on glomerular basement membranes. The findings indicated stage I membranous glomerulonephritis. Administration of ursodesoxycholic acid together with prednisolone, azathioprine, and dipyridamole decreased proteinuria and improved cholestatic liver dysfunction.  (+info)

Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans. (2/432)

BACKGROUND: Stimulated bile acid synthesis preferentially utilises newly synthesised cholesterol, raising the possibility that combination of simvastatin (an inhibitor of cholesterol synthesis) with ursodeoxycholic acid (UDCA; a stimulator of bile acid synthesis) may result in reduced bile acid synthesis and greater enrichment of the pool with UDCA than that achieved with UDCA treatment alone. AIMS: To investigate the effect of simvastatin and UDCA given alone and in combination on serum and biliary lipid and biliary bile acid composition. METHODS: Eighteen patients with primary non-familial hypercholesterolaemia were studied during treatment with simvastatin 20 mg/day, UDCA 10 mg/kg/day, and a combination of the two drugs. Each regimen was given in random order for three months following a three month lead in period. RESULTS: Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol but biliary cholesterol concentration remained unchanged. Combination of the two drugs had no synergistic effect on serum cholesterol concentration, but significantly increased the proportion of UDCA in the bile acid pool from 35% during UDCA to 48% during combination treatment (p<0.04). CONCLUSIONS: Results showed that: (1) simvastatin reduces serum LDL cholesterol but has no effect on biliary cholesterol concentration, supporting the concept that newly synthesised cholesterol is not the preferential source for biliary cholesterol; and (2) combination of simvastatin with UDCA has the predicted effect of enhancing the proportion of UDCA in the pool. This effect may be of benefit in the treatment of cholestatic liver diseases.  (+info)

The effect of bile salts and calcium on isolated rat liver mitochondria. (3/432)

Intact mitochondria were incubated with and without calcium in solutions of chenodeoxycholate, ursodeoxycholate, or their conjugates. Glutamate dehydrogenase, protein and phospholipid release were measured. Alterations in membrane and organelle structure were investigated by electron paramagnetic resonance spectroscopy. Chenodeoxycholate enhanced enzyme liberation, solubilized protein and phospholipid, and increased protein spin label mobility and the polarity of the hydrophobic membrane interior, whereas ursodeoxycholate and its conjugates did not damage mitochondria. Preincubation with ursodeoxycholate or its conjugate tauroursodeoxycholate for 20 min partially prevented damage by chenodeoxycholate. Extended preincubation even with 1 mM ursodeoxycholate could no longer prevent structural damage. Calcium (from 0.01 mM upward) augmented the damaging effect of chenodeoxycholate (0.15-0.5 mM). The combined action of 0.01 mM calcium and 0.15 mM chenodeoxycholate was reversed by ursodeoxycholate only, not by its conjugates tauroursodeoxycholate and glycoursodeoxycholate. In conclusion, ursodeoxycholate partially prevents chenodeoxycholate-induced glutamate dehydrogenase release from liver cell mitochondria by membrane stabilization. This holds for shorter times and at concentrations below 0.5 mM only, indicating that the different constitution of protein-rich mitochondrial membranes does not allow optimal stabilization such as has been seen in phospholipid- and cholesterol-rich hepatocyte cell membranes, investigated previously.  (+info)

Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. (4/432)

Systemic arterial vasodilatation has been implicated in the pathogenesis of sodium retention in cirrhosis. Hydrophobic bile acids, which have vasodilatory actions, may be involved. Ursodeoxycholic acid, a hydrophilic bile acid, could potentially decrease systemic arterial vasodilatation, possibly due to its antioxidant effects, and improve sodium handling in cirrhosis. The effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics, liver function and renal sodium handling were assessed in vasodilated cirrhotic patients with refractory ascites treated with a transjugular intrahepatic porto-systemic shunt (TIPS). Eight cirrhotic patients with refractory ascites without TIPS placement served as controls for the sodium handling effects of ursodeoxycholic acid. From 1 month post TIPS, seven patients were studied before, after 1 month of treatment with ursodeoxycholic acid (15 mg.day-1.kg-1) and at 1 month follow-up. Lipid peroxidation products were used as indices of its antioxidant effects. Ursodeoxycholic acid caused a significant reduction in sodium excretion in both groups (P<0.05). This, in the post-TIPS patients (urinary sodium excretion: 35+/-8 mmol/day at 1 month versus 93+/-21 mmol/day at baseline, P<0.05), was due to a significant increase in sodium reabsorption proximal to the distal tubule (P<0.05), without any significant changes in systemic, renal or forearm haemodynamics, or in liver function. No significant change in lipid peroxidation products was observed. We conclude that: (i) in cirrhotic patients with refractory ascites, ursodeoxycholic acid causes sodium retention, (ii) the abnormality in sodium handling in the post-TIPS cirrhotic patients appears to be the result of a direct effect on the proximal nephron, suggesting that factors other than systemic vasodilatation also contribute to sodium retention in cirrhosis, (iii) caution should be exercised in administering ursodeoxycholic acid in cirrhotic patients with ascites.  (+info)

Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. (5/432)

Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed by a high-pressure liquid chromatography method that had been validated against gas chromatography. Percent composition in bile (mean +/- SD) for 98 patients at entry for cholic (CA), chenodeoxycholic (CDCA), deoxycholic (DCA), lithocholic (LCA), and ursodeoxycholic (UDCA) acids, respectively, were 57.4 +/- 18.6, 31.5 +/- 15.5, 8.0 +/- 9.3, 0.3 +/- 1.0, and 0.6 +/- 0.9. Values for CA were increased, whereas those for CDCA, DCA, LCA, and UDCA were decreased when compared with values in normal persons. Bile acid composition of the major bile acids did not change after 2 years on placebo medication. By contrast, in patients receiving UDCA for 2 years, bile became enriched with UDCA on average to 40.1%, and significant decreases were noted for CA (to 32.2%) and CDCA (to 19.5%). No change in percent composition was observed for DCA and LCA. Percent composition at entry and changes in composition after 2 years on UDCA were similar in patients with varying severity of PBC. In patients whose bile was not enriched in UDCA (entry and placebo-treated specimens), CA, CDCA, DCA, and the small amount of UDCA found in some of these specimens were conjugated to a greater extent with glycine (52%-64%) than with taurine (36%-48%). Treatment with UDCA caused the proportion of all endogenous bile acids conjugated with glycine to increase to 69% to 78%, while the proportion conjugated with taurine (22%-31%) fell (P <.05). Administered UDCA was also conjugated predominantly with glycine (87%).  (+info)

Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. (6/432)

AIMS: Ursodeoxycholic acid (UDCA) has cholesterol lowering and anti-inflammatory effects and bile acids are reported to exert vasodilator effects; all of these properties might be considered desirable in a drug used in the treatment of patients with coronary heart disease. We investigated a hypothesis that UDCA may dilate arteries and the mechanism of action. METHODS: We evaluated effects of a 6-week treatment with UDCA in 11 coronary heart disease patients on endothelium-dependent (acetylcholine-induced) and -independent (nitroprusside-induced) vasodilatations in forearm vasculature by strain-gauge plethysmography. Healthy individuals (n=14) served as baseline controls. RESULTS: The percentage increase by acetylcholine in the flow of the infused arm relative to the non-infused arm of coronary heart disease patients during the trial remained unaltered, but vasodilatation to NG-monomethyl-l-arginine+acetylcholine was improved by 161+/-27% with UDCA vs 83+/-22% with placebo (mean difference 91% [95% CI 35%, 147%], P=0.016). CONCLUSIONS: Six weeks' UDCA therapy improved endothelium-dependent nitric oxide-independent vasodilatation, which might maintain arterial flow in coronary heart disease patients under conditions of impaired nitric oxide production.  (+info)

Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. (7/432)

BACKGROUND: Data on meconium bile acid composition in newborn babies of patients with intrahepatic cholestasis of pregnancy (ICP) are relatively scant, and changes that occur on ursodeoxycholic acid (UDCA) administration have not been evaluated. AIMS: To investigate bile acid profiles in meconium of neonates from untreated and UDCA treated patients with ICP. Maternal serum bile acid composition was also analysed both at diagnosis and delivery to determine whether this influences the concentration and proportion of bile acids in the meconium. PATIENTS/METHODS: The population included eight healthy pregnant women and 16 patients with ICP, nine of which received UDCA (12.5-15.0 mg/kg body weight/day) for 15+/-4 days until parturition. Bile acids were assessed in the meconium by gas chromatography-mass spectrometry and in maternal serum by high performance liquid chromatography. RESULTS: Total bile acid and cholic acid concentrations in the meconium were increased (p<0.01) in newborns from patients with ICP (13.5 (5.1) and 8.4 (4.1) micromol/g respectively; mean (SEM)) as compared with controls (2.0 (0.5) and 0.8 (0.3) micromol/g respectively), reflecting the total bile acid and cholic acid levels in the maternal serum (r = 0.85 and r = 0.84, p<0.01). After UDCA administration, total bile acid concentrations decreased in the mother ( approximately 3-fold, p<0. 05) but not in the meconium. UDCA concentration in the meconium showed only a 2-fold increase after treatment, despite the much greater increase in the maternal serum (p<0.01). Lithocholic acid concentration in the meconium was not increased by UDCA treatment. CONCLUSIONS: UDCA administration does not influence the concentration and proportion of bile acids in the meconium, which in turn are altered by ICP. Moreover, this beneficial treatment for the mother does not increase meconium levels of potentially toxic metabolites of UDCA such as lithocholic acid.  (+info)

The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. (8/432)

The frequency with which florid duct lesions are seen in needle-biopsy specimens of the liver was assessed in patients with primary biliary cirrhosis (PBC) enrolled in a 2-year randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) versus placebo. Paired biopsy specimens obtained at entry and after 2 years on medication were reviewed blindly and mostly simultaneously by a panel of 5 hepatopathologists who, earlier, had characterized the florid duct lesion, which has been well described in the pathology literature. Florid duct lesions at entry were identified in approximately 36%. Patients with earlier disease showed florid duct lesions much more frequently than those with more advanced disease. The prevalence of florid duct lesions in 60 patients receiving placebo medication fell from 38.3% to 21.7%, P =. 025, over the period of 2 years. The prevalence of florid duct lesions also decreased in the 55 patients receiving UDCA, from 32.7% to 18.2%, P =.046. The prevalences of these lesions in the placebo and UDCA patients at entry and at 2 years were not significantly different from each other. The findings suggest that UDCA does not prevent ongoing bile duct destruction in patients with PBC. Instead, they support the impression that UDCA exerts its beneficial effects by protecting against the consequences of bile duct destruction.  (+info)

Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid that is used medically as a therapeutic agent. It is commonly used to treat gallstones, particularly cholesterol gallstones, and other conditions associated with abnormal liver function, such as primary biliary cholangitis (PBC). UDCA works by decreasing the amount of cholesterol in bile and protecting liver cells from damage. It is also known as ursodiol or Ursotan.

Cholagogues and choleretics are terms used to describe medications or substances that affect bile secretion and flow in the body. Here is a medical definition for each:

1. Cholagogue: A substance that promotes the discharge of bile from the gallbladder into the duodenum, often by stimulating the contraction of the gallbladder muscle. This helps in the digestion and absorption of fats. Examples include chenodeoxycholic acid, ursodeoxycholic acid, and some herbal remedies like dandelion root and milk thistle.
2. Choleretic: A substance that increases the production of bile by the liver or its flow through the biliary system. This can help with the digestion of fats and the elimination of waste products from the body. Examples include certain medications like ursodeoxycholic acid, as well as natural substances such as lemon juice, artichoke extract, and turmeric.

It is important to note that while cholagogues and choleretics can aid in digestion, they should be used under the guidance of a healthcare professional, as improper use or overuse may lead to complications like diarrhea or gallstone formation.

Deoxycholic acid is a bile acid, which is a natural molecule produced in the liver and released into the intestine to aid in the digestion of fats. It is also a secondary bile acid, meaning that it is formed from the metabolism of primary bile acids by bacteria in the gut.

Deoxycholic acid has a chemical formula of C~24~H~39~NO~4~ and a molecular weight of 391.57 g/mol. It is a white crystalline powder that is soluble in water and alcohol. In the body, deoxycholic acid acts as a detergent to help break down dietary fats into smaller droplets, which can then be absorbed by the intestines.

In addition to its role in digestion, deoxycholic acid has been investigated for its potential therapeutic uses. For example, it is approved by the US Food and Drug Administration (FDA) as an injectable treatment for reducing fat in the submental area (the region below the chin), under the brand name Kybella. When injected into this area, deoxycholic acid causes the destruction of fat cells, which are then naturally eliminated from the body over time.

It's important to note that while deoxycholic acid is a natural component of the human body, its therapeutic use can have potential side effects and risks, so it should only be used under the supervision of a qualified healthcare professional.

Chenodeoxycholic acid (CDCA) is a bile acid that is naturally produced in the human body. It is formed in the liver from cholesterol and is then conjugated with glycine or taurine to become a primary bile acid. CDCA is stored in the gallbladder and released into the small intestine during digestion, where it helps to emulsify fats and facilitate their absorption.

CDCA also has important regulatory functions in the body, including acting as a signaling molecule that binds to specific receptors in the liver, intestines, and other tissues. It plays a role in glucose and lipid metabolism, inflammation, and cell growth and differentiation.

In addition to its natural functions, CDCA is also used as a medication for the treatment of certain medical conditions. For example, it is used to dissolve gallstones that are composed of cholesterol, and it is also used to treat a rare genetic disorder called cerebrotendinous xanthomatosis (CTX), which is characterized by the accumulation of CDCA and other bile acids in various tissues.

It's important to note that while CDCA has therapeutic uses, it can also have adverse effects if taken in high doses or for extended periods of time. Therefore, it should only be used under the supervision of a healthcare professional.

Lithocholic acid (LCA) is a secondary bile acid that is produced in the liver by bacterial modification of primary bile acids, specifically chenodeoxycholic acid. It is a steroid acid that plays a role in various physiological processes such as cholesterol metabolism, drug absorption, and gut microbiota regulation. However, high levels of LCA can be toxic to the liver and have been linked to several diseases, including colon cancer and cholestatic liver diseases.

Bile acids and salts are naturally occurring steroidal compounds that play a crucial role in the digestion and absorption of lipids (fats) in the body. They are produced in the liver from cholesterol and then conjugated with glycine or taurine to form bile acids, which are subsequently converted into bile salts by the addition of a sodium or potassium ion.

Bile acids and salts are stored in the gallbladder and released into the small intestine during digestion, where they help emulsify fats, allowing them to be broken down into smaller molecules that can be absorbed by the body. They also aid in the elimination of waste products from the liver and help regulate cholesterol metabolism.

Abnormalities in bile acid synthesis or transport can lead to various medical conditions, such as cholestatic liver diseases, gallstones, and diarrhea. Therefore, understanding the role of bile acids and salts in the body is essential for diagnosing and treating these disorders.

Biliary cirrhosis is a specific type of liver cirrhosis that results from chronic inflammation and scarring of the bile ducts, leading to impaired bile flow, liver damage, and fibrosis. It can be further classified into primary biliary cholangitis (PBC) and secondary biliary cirrhosis. PBC is an autoimmune disease, while secondary biliary cirrhosis is often associated with chronic gallstones, biliary tract obstruction, or recurrent pyogenic cholangitis. Symptoms may include fatigue, itching, jaundice, and abdominal discomfort. Diagnosis typically involves blood tests, imaging studies, and sometimes liver biopsy. Treatment focuses on managing symptoms, slowing disease progression, and preventing complications.

Bile is a digestive fluid that is produced by the liver and stored in the gallbladder. It plays an essential role in the digestion and absorption of fats and fat-soluble vitamins in the small intestine. Bile consists of bile salts, bilirubin, cholesterol, phospholipids, electrolytes, and water.

Bile salts are amphipathic molecules that help to emulsify fats into smaller droplets, increasing their surface area and allowing for more efficient digestion by enzymes such as lipase. Bilirubin is a breakdown product of hemoglobin from red blood cells and gives bile its characteristic greenish-brown color.

Bile is released into the small intestine in response to food, particularly fats, entering the digestive tract. It helps to break down large fat molecules into smaller ones that can be absorbed through the walls of the intestines and transported to other parts of the body for energy or storage.

Taurochenodeoxycholic acid (TCDCA) is a bile acid that is conjugated with the amino acid taurine. Bile acids are synthesized from cholesterol in the liver and released into the small intestine to aid in the digestion and absorption of fats and fat-soluble vitamins. TCDCA, along with other bile acids, is reabsorbed in the terminal ileum and transported back to the liver through the enterohepatic circulation. It plays a role in maintaining cholesterol homeostasis and has been studied for its potential therapeutic effects in various medical conditions, including gallstones, cholestatic liver diseases, and neurological disorders.

Intrahepatic cholestasis is a medical condition characterized by the interruption or reduction of bile flow within the liver. Bile is a digestive fluid produced by the liver that helps in the absorption of fats and fat-soluble vitamins. Intrahepatic cholestasis occurs when there is a problem with the transport of bile components inside the liver cells (hepatocytes). This can lead to an accumulation of bile acids, bilirubin, and other substances in the liver, which can cause damage to liver cells and result in symptoms such as jaundice, itching, and dark urine.

Intrahepatic cholestasis can be caused by various factors, including medications, alcohol abuse, hepatitis viruses, autoimmune disorders, genetic defects, and cancer. Depending on the underlying cause, intrahepatic cholestasis can be acute or chronic, and it can range from mild to severe. Treatment typically involves addressing the underlying cause of the condition, as well as providing supportive care to manage symptoms and prevent complications.

Cholelithiasis is a medical term that refers to the presence of gallstones in the gallbladder. The gallbladder is a small pear-shaped organ located beneath the liver that stores bile, a digestive fluid produced by the liver. Gallstones are hardened deposits that can form in the gallbladder when substances in the bile, such as cholesterol or bilirubin, crystallize.

Gallstones can vary in size and may be as small as a grain of sand or as large as a golf ball. Some people with gallstones may not experience any symptoms, while others may have severe abdominal pain, nausea, vomiting, fever, and jaundice (yellowing of the skin and eyes) if the gallstones block the bile ducts.

Cholelithiasis is a common condition that affects millions of people worldwide, particularly women over the age of 40 and those with certain medical conditions such as obesity, diabetes, and rapid weight loss. If left untreated, gallstones can lead to serious complications such as inflammation of the gallbladder (cholecystitis), infection, or pancreatitis (inflammation of the pancreas). Treatment options for cholelithiasis include medication, shock wave lithotripsy (breaking up the gallstones with sound waves), and surgery to remove the gallbladder (cholecystectomy).

Cholic acids are a type of bile acid, which are naturally occurring steroid acids that play a crucial role in the digestion and absorption of fats and fat-soluble vitamins in the body. Cholic acid is the primary bile acid synthesized in the liver from cholesterol. It is then conjugated with glycine or taurine to form conjugated cholic acids, which are stored in the gallbladder and released into the small intestine during digestion to aid in fat emulsification and absorption.

Cholic acid and its derivatives have also been studied for their potential therapeutic benefits in various medical conditions, including liver diseases, gallstones, and bacterial infections. However, more research is needed to fully understand the mechanisms of action and potential side effects of cholic acids and their derivatives before they can be widely used as therapeutic agents.

Cholic acid is a primary bile acid, which is a type of organic compound that plays a crucial role in the digestion and absorption of fats and fat-soluble vitamins in the body. It is produced in the liver from cholesterol and is then conjugated with glycine or taurine to form conjugated bile acids, which are stored in the gallbladder and released into the small intestine during digestion.

Cholic acid helps to emulsify fats, allowing them to be broken down into smaller droplets that can be absorbed by the body. It also facilitates the absorption of fat-soluble vitamins such as vitamin A, D, E, and K. In addition to its role in digestion, cholic acid is also involved in the regulation of cholesterol metabolism and the excretion of bile acids from the body.

Abnormalities in cholic acid metabolism can lead to various medical conditions, such as cholestatic liver diseases, gallstones, and genetic disorders that affect bile acid synthesis.

Cholestasis is a medical condition characterized by the interruption or reduction of bile flow from the liver to the small intestine. Bile is a digestive fluid produced by the liver that helps in the breakdown and absorption of fats. When the flow of bile is blocked or reduced, it can lead to an accumulation of bile components, such as bilirubin, in the blood, which can cause jaundice, itching, and other symptoms.

Cholestasis can be caused by various factors, including liver diseases (such as hepatitis, cirrhosis, or cancer), gallstones, alcohol abuse, certain medications, pregnancy, and genetic disorders. Depending on the underlying cause, cholestasis may be acute or chronic, and it can range from mild to severe in its symptoms and consequences. Treatment for cholestasis typically involves addressing the underlying cause and managing the symptoms with supportive care.

Sclerosing cholangitis is a chronic progressive disease characterized by inflammation and scarring (fibrosis) of the bile ducts, leading to their narrowing or obstruction. This results in impaired bile flow from the liver to the small intestine, which can cause damage to the liver cells and eventually result in cirrhosis and liver failure.

The condition often affects both the intrahepatic (within the liver) and extrahepatic (outside the liver) bile ducts. The exact cause of sclerosing cholangitis is not known, but it is believed to involve an autoimmune response, genetic predisposition, and environmental factors.

Symptoms of sclerosing cholangitis may include jaundice (yellowing of the skin and eyes), itching, abdominal pain, fatigue, weight loss, dark urine, and light-colored stools. The diagnosis is typically made through imaging tests such as magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP), which can visualize the bile ducts and detect any abnormalities.

Treatment for sclerosing cholangitis is aimed at managing symptoms, preventing complications, and slowing down the progression of the disease. This may include medications to relieve itching, antibiotics to treat infections, and drugs to reduce inflammation and improve bile flow. In severe cases, a liver transplant may be necessary.

Dehydrocholic acid is not typically considered a medical term, but it does have relevance to the field of medicine as a gastrointestinal stimulant and choleretic agent. Here's a brief definition:

Dehydrocholic acid (C~24~H~39~NO~5~) is a bile salt that is formed from cholic acid through the introduction of a double bond between carbons 7 and 8. It is used in medical research and practice as a pharmacological agent to stimulate the production and flow of bile from the liver, which can aid in digestion and absorption of fats. Dehydrocholic acid may also be used in diagnostic tests to assess liver function and biliary tract patency.

It is important to note that dehydrocholic acid is not commonly used as a therapeutic agent in clinical practice due to the availability of safer and more effective alternatives for treating gastrointestinal disorders and promoting liver health.

Selenium radioisotopes are unstable forms of the element selenium that emit radiation as they decay into more stable forms. These isotopes can be produced through various nuclear reactions, such as irradiating a stable selenium target with protons or alpha particles. Some examples of selenium radioisotopes include selenium-75, selenium-79, and selenium-81.

Selenium-75 is commonly used in medical imaging to study the function of the thyroid gland, as it accumulates in this gland and can be detected using a gamma camera. Selenium-79 and selenium-81 have potential uses in cancer treatment, as they can be incorporated into compounds that selectively target and destroy cancer cells. However, more research is needed to fully understand the potential benefits and risks of using these radioisotopes in medical treatments.

It's important to note that handling and using radioisotopes requires special training and precautions, as they can be dangerous if not handled properly. Exposure to radiation from radioisotopes can increase the risk of cancer and other health problems, so it's essential to use them only under controlled conditions and with appropriate safety measures in place.

A hepatic portoenterostomy, also known as Kasai procedure, is a surgical operation performed on infants with extrahepatic biliary atresia. This condition is characterized by the absence or abnormal formation of the bile ducts that carry bile from the liver to the small intestine, leading to obstruction and damage to the liver.

During a hepatic portoenterostomy, the surgeon creates an anastomosis (connection) between the portal vein, which brings blood to the liver, and a loop of intestine. This connection allows bile to flow directly from the liver into the intestine, bypassing the blocked or absent bile ducts. The goal of the procedure is to restore bile flow and prevent further damage to the liver.

The success of the procedure varies, but it can help improve the child's quality of life and delay or prevent the need for a liver transplant in some cases. However, many children with biliary atresia will eventually require a liver transplant as the disease progresses.

Glycochenodeoxycholic acid (GCDCA) is a type of bile acid that is produced in the liver and then conjugated with glycine. Bile acids are formed from cholesterol and play an important role in the digestion and absorption of fats and fat-soluble vitamins in the small intestine.

GCDCA is a secondary bile acid, which means that it is produced by bacterial metabolism of primary bile acids (such as cholic acid and chenodeoxycholic acid) in the colon. Once formed, GCDCA is then reabsorbed into the bloodstream and transported back to the liver, where it can be conjugated with glycine or taurine and excreted into bile again.

Abnormal levels of GCDCA and other bile acids have been associated with various health conditions, including cholestatic liver diseases, gallstones, and colon cancer. Therefore, measuring the levels of these acids in blood, urine, or feces can provide valuable diagnostic information for these conditions.

Autoimmune hepatitis is a chronic (long-term) disease in which the body's immune system mistakenly attacks the liver, leading to inflammation and damage. This results in decreased liver function over time if not treated. The exact cause of autoimmune hepatitis is unknown, but it is believed to be associated with genetic factors and exposure to certain environmental triggers, such as viral infections or medications.

There are two main types of autoimmune hepatitis:

1. Type 1 (classic) autoimmune hepatitis: This form can affect both adults and children, and it is more common in women than men. People with this type may also have other autoimmune disorders, such as rheumatoid arthritis, thyroid disease, or ulcerative colitis.
2. Type 2 autoimmune hepatitis: This form primarily affects children and young women. It is less common than type 1 and tends to be more severe. People with this type may also have other autoimmune disorders, such as celiac disease or chronic candidiasis.

Symptoms of autoimmune hepatitis can vary widely, from mild to severe. They may include fatigue, loss of appetite, nausea, vomiting, abdominal pain, joint pain, jaundice (yellowing of the skin and eyes), dark urine, and light-colored stools.

Diagnosis typically involves blood tests, imaging studies, and sometimes a liver biopsy to assess the extent of damage. Treatment usually includes medications that suppress the immune system, such as corticosteroids and immunosuppressants, which can help reduce inflammation and slow or stop liver damage. In some cases, lifestyle changes and supportive care may also be necessary.

Bilirubin is a yellowish pigment that is produced by the liver when it breaks down old red blood cells. It is a normal byproduct of hemoglobin metabolism and is usually conjugated (made water-soluble) in the liver before being excreted through the bile into the digestive system. Elevated levels of bilirubin can cause jaundice, a yellowing of the skin and eyes. Increased bilirubin levels may indicate liver disease or other medical conditions such as gallstones or hemolysis. It is also measured to assess liver function and to help diagnose various liver disorders.

I'm sorry for any confusion, but "Glycocholic Acid" is not a widely recognized or established medical term. It seems there might be a misunderstanding or a typo in your request.

If you meant "Glycocholic," it's a term that refers to a substance conjugated with glycine, which is an amino acid. This process often occurs in the liver during the metabolism of certain substances, like bile acids.

"Glycocholic" could theoretically refer to a glycine conjugate of a bile acid such as cholic acid, which would make it a derivative called "Glycocholic Acid." However, I couldn't find any specific medical or scientific literature that directly refers to "Glycocholic Acid" as a known compound or concept.

If you could provide more context or clarify your question, I would be happy to help further!

Glycodeoxycholic acid (GDCA) is not a widely recognized or established medical term. However, it appears to be a chemical compound that can be formed as a result of the metabolic process in the body. It is a glycine-conjugated bile acid, which means that it is a combination of the bile acid deoxycholic acid and the amino acid glycine.

Bile acids are produced by the liver to help with the digestion and absorption of fats in the small intestine. They are conjugated, or combined, with amino acids like glycine or taurine before being released into the bile. These conjugated bile acids help to keep the bile acid salts in their soluble form and prevent them from being reabsorbed back into the bloodstream.

Glycodeoxycholic acid may be involved in various physiological processes, but there is limited research on its specific functions or medical significance. If you have any concerns about this compound or its potential impact on your health, it would be best to consult with a healthcare professional for more information.

Liver function tests (LFTs) are a group of blood tests that are used to assess the functioning and health of the liver. These tests measure the levels of various enzymes, proteins, and waste products that are produced or metabolized by the liver. Some common LFTs include:

1. Alanine aminotransferase (ALT): An enzyme found primarily in the liver, ALT is released into the bloodstream in response to liver cell damage. Elevated levels of ALT may indicate liver injury or disease.
2. Aspartate aminotransferase (AST): Another enzyme found in various tissues, including the liver, heart, and muscles. Like ALT, AST is released into the bloodstream following tissue damage. High AST levels can be a sign of liver damage or other medical conditions.
3. Alkaline phosphatase (ALP): An enzyme found in several organs, including the liver, bile ducts, and bones. Elevated ALP levels may indicate a blockage in the bile ducts, liver disease, or bone disorders.
4. Gamma-glutamyl transferase (GGT): An enzyme found mainly in the liver, pancreas, and biliary system. Increased GGT levels can suggest liver disease, alcohol consumption, or the use of certain medications.
5. Bilirubin: A yellowish pigment produced when hemoglobin from red blood cells is broken down. Bilirubin is processed by the liver and excreted through bile. High bilirubin levels can indicate liver dysfunction, bile duct obstruction, or certain types of anemia.
6. Albumin: A protein produced by the liver that helps maintain fluid balance in the body and transports various substances in the blood. Low albumin levels may suggest liver damage, malnutrition, or kidney disease.
7. Total protein: A measure of all proteins present in the blood, including albumin and other types of proteins produced by the liver. Decreased total protein levels can indicate liver dysfunction or other medical conditions.

These tests are often ordered together as part of a routine health checkup or when evaluating symptoms related to liver function or disease. The results should be interpreted in conjunction with clinical findings, medical history, and other diagnostic tests.

Taurine is an organic compound that is widely distributed in animal tissues. It is a conditionally essential amino acid, meaning it can be synthesized by the human body under normal circumstances, but there may be increased requirements during certain periods such as infancy, infection, or illness. Taurine plays important roles in various physiological functions, including bile salt formation, membrane stabilization, neuromodulation, and antioxidation. It is particularly abundant in the brain, heart, retina, and skeletal muscles. In the human body, taurine is synthesized from the amino acids cysteine and methionine with the aid of vitamin B6.

Taurine can also be found in certain foods like meat, fish, and dairy products, as well as in energy drinks, where it is often added as a supplement for its potential performance-enhancing effects. However, there is ongoing debate about the safety and efficacy of taurine supplementation in healthy individuals.

Pruritus is a medical term derived from Latin, in which "prurire" means "to itch." It refers to an unpleasant sensation on the skin that provokes the desire or reflex to scratch. This can be caused by various factors, such as skin conditions (e.g., dryness, eczema, psoriasis), systemic diseases (e.g., liver disease, kidney failure), nerve disorders, psychological conditions, or reactions to certain medications.

Pruritus can significantly affect a person's quality of life, leading to sleep disturbances, anxiety, and depression. Proper identification and management of the underlying cause are essential for effective treatment.

Hepatic insufficiency, also known as liver insufficiency, refers to the reduced ability of the liver to perform its vital functions due to damage or disease. The liver plays a crucial role in metabolism, detoxification, synthesis, storage, and secretion. When it becomes insufficient, it can lead to various complications such as:

1. Impaired metabolism of carbohydrates, fats, and proteins
2. Buildup of toxic substances in the blood due to reduced detoxification capacity
3. Decreased synthesis of essential proteins, including clotting factors
4. Reduced glycogen storage and impaired glucose regulation
5. Fluid accumulation in the abdomen (ascites) and legs (edema) due to decreased production of albumin and increased pressure in the portal vein
6. Impaired immune function, making the individual more susceptible to infections
7. Hormonal imbalances leading to various symptoms such as changes in appetite, weight loss, and sexual dysfunction

Hepatic insufficiency can range from mild to severe, and if left untreated, it may progress to liver failure, a life-threatening condition requiring immediate medical attention.

Cholecystography is a medical procedure that involves the use of X-rays to examine the gallbladder and bile ducts. It is also known as an oral cholecystogram (OCG).

The procedure involves administering a contrast agent, typically a iodine-based dye, which is absorbed by the liver and excreted into the bile ducts and gallbladder. The dye makes the bile ducts and gallbladder visible on X-ray images, allowing doctors to diagnose conditions such as gallstones, tumors, or inflammation of the gallbladder.

Cholecystography is not commonly used today due to the development of more advanced imaging techniques, such as ultrasound and computed tomography (CT) scans, which are non-invasive and do not require the use of contrast agents. However, it may still be used in certain cases where other imaging tests are inconclusive or unavailable.

Cholesterol is a type of lipid (fat) molecule that is an essential component of cell membranes and is also used to make certain hormones and vitamins in the body. It is produced by the liver and is also obtained from animal-derived foods such as meat, dairy products, and eggs.

Cholesterol does not mix with blood, so it is transported through the bloodstream by lipoproteins, which are particles made up of both lipids and proteins. There are two main types of lipoproteins that carry cholesterol: low-density lipoproteins (LDL), also known as "bad" cholesterol, and high-density lipoproteins (HDL), also known as "good" cholesterol.

High levels of LDL cholesterol in the blood can lead to a buildup of cholesterol in the walls of the arteries, increasing the risk of heart disease and stroke. On the other hand, high levels of HDL cholesterol are associated with a lower risk of these conditions because HDL helps remove LDL cholesterol from the bloodstream and transport it back to the liver for disposal.

It is important to maintain healthy levels of cholesterol through a balanced diet, regular exercise, and sometimes medication if necessary. Regular screening is also recommended to monitor cholesterol levels and prevent health complications.

The liver is a large, solid organ located in the upper right portion of the abdomen, beneath the diaphragm and above the stomach. It plays a vital role in several bodily functions, including:

1. Metabolism: The liver helps to metabolize carbohydrates, fats, and proteins from the food we eat into energy and nutrients that our bodies can use.
2. Detoxification: The liver detoxifies harmful substances in the body by breaking them down into less toxic forms or excreting them through bile.
3. Synthesis: The liver synthesizes important proteins, such as albumin and clotting factors, that are necessary for proper bodily function.
4. Storage: The liver stores glucose, vitamins, and minerals that can be released when the body needs them.
5. Bile production: The liver produces bile, a digestive juice that helps to break down fats in the small intestine.
6. Immune function: The liver plays a role in the immune system by filtering out bacteria and other harmful substances from the blood.

Overall, the liver is an essential organ that plays a critical role in maintaining overall health and well-being.

Bile ducts are tubular structures that carry bile from the liver to the gallbladder for storage or directly to the small intestine to aid in digestion. There are two types of bile ducts: intrahepatic and extrahepatic. Intrahepatic bile ducts are located within the liver and drain bile from liver cells, while extrahepatic bile ducts are outside the liver and include the common hepatic duct, cystic duct, and common bile duct. These ducts can become obstructed or inflamed, leading to various medical conditions such as cholestasis, cholecystitis, and gallstones.

Biliary atresia is a rare, progressive liver disease in infants and children, characterized by the inflammation, fibrosis, and obstruction of the bile ducts. This results in the impaired flow of bile from the liver to the intestine, leading to cholestasis (accumulation of bile in the liver), jaundice (yellowing of the skin and eyes), and eventually liver cirrhosis and failure if left untreated.

The exact cause of biliary atresia is not known, but it is believed to be a combination of genetic and environmental factors. It can occur as an isolated condition or in association with other congenital anomalies. The diagnosis of biliary atresia is typically made through imaging studies, such as ultrasound and cholangiography, and confirmed by liver biopsy.

The standard treatment for biliary atresia is a surgical procedure called the Kasai portoenterostomy, which aims to restore bile flow from the liver to the intestine. In this procedure, the damaged bile ducts are removed and replaced with a loop of intestine that is connected directly to the liver. The success of the Kasai procedure depends on several factors, including the age at diagnosis and surgery, the extent of liver damage, and the skill and experience of the surgeon.

Despite successful Kasai surgery, many children with biliary atresia will eventually develop cirrhosis and require liver transplantation. The prognosis for children with biliary atresia has improved significantly over the past few decades due to earlier diagnosis, advances in surgical techniques, and better postoperative care. However, it remains a challenging condition that requires close monitoring and multidisciplinary management by pediatric hepatologists, surgeons, and other healthcare professionals.

Taurocholic acid is a bile salt, which is a type of organic compound that plays a crucial role in the digestion and absorption of fats and fat-soluble vitamins in the small intestine. It is formed in the liver by conjugation of cholic acid with taurine, an amino sulfonic acid.

Taurocholic acid has a detergent-like effect on the lipids in our food, helping to break them down into smaller molecules that can be absorbed through the intestinal wall and transported to other parts of the body for energy production or storage. It also helps to maintain the flow of bile from the liver to the gallbladder and small intestine, where it is stored until needed for digestion.

Abnormal levels of taurocholic acid in the body have been linked to various health conditions, including gallstones, liver disease, and gastrointestinal disorders. Therefore, it is important to maintain a healthy balance of bile salts, including taurocholic acid, for optimal digestive function.

Gallstones are small, hard deposits that form in the gallbladder, a small organ located under the liver. They can range in size from as small as a grain of sand to as large as a golf ball. Gallstones can be made of cholesterol, bile pigments, or calcium salts, or a combination of these substances.

There are two main types of gallstones: cholesterol stones and pigment stones. Cholesterol stones are the most common type and are usually yellow-green in color. They form when there is too much cholesterol in the bile, which causes it to become saturated and form crystals that eventually grow into stones. Pigment stones are smaller and darker in color, ranging from brown to black. They form when there is an excess of bilirubin, a waste product produced by the breakdown of red blood cells, in the bile.

Gallstones can cause symptoms such as abdominal pain, nausea, vomiting, and bloating, especially after eating fatty foods. In some cases, gallstones can lead to serious complications, such as inflammation of the gallbladder (cholecystitis), infection, or blockage of the bile ducts, which can cause jaundice, a yellowing of the skin and eyes.

The exact cause of gallstones is not fully understood, but risk factors include being female, older age, obesity, a family history of gallstones, rapid weight loss, diabetes, and certain medical conditions such as cirrhosis or sickle cell anemia. Treatment for gallstones may involve medication to dissolve the stones, shock wave therapy to break them up, or surgery to remove the gallbladder.

I believe there might be a slight confusion in your question. Sulfuric acid is not a medical term, but instead a chemical compound with the formula H2SO4. It's one of the most important industrial chemicals, being a strong mineral acid with numerous applications.

If you are asking for a definition related to human health or medicine, I can tell you that sulfuric acid has no physiological role in humans. Exposure to sulfuric acid can cause irritation and burns to the skin, eyes, and respiratory tract. Prolonged exposure may lead to more severe health issues. However, it is not a term typically used in medical diagnoses or treatments.

Azoxymethane is a chemical compound that is used primarily in laboratory research. It is an organodihydroazoxy compound, and it is known to cause colon cancer in experimental animals, particularly rats and mice. As such, it is often used as a tool in studies of carcinogenesis and chemically induced colon tumors.

In scientific studies, azoxymethane is typically administered to laboratory animals in order to induce colon tumors. This allows researchers to study the mechanisms of cancer development and test potential therapies or preventive measures. It is important to note that while azoxymethane has been shown to cause cancer in laboratory animals, it does not necessarily mean that it poses the same risk to humans.

The use of azoxymethane in research is subject to strict regulations and guidelines, as with any potentially hazardous chemical. Researchers are required to follow safety protocols and take appropriate precautions when handling this compound to minimize risks to themselves and the environment.

Hydroxysteroid dehydrogenases (HSDs) are a group of enzymes that play a crucial role in steroid hormone metabolism. They catalyze the oxidation and reduction reactions of hydroxyl groups on the steroid molecule, which can lead to the activation or inactivation of steroid hormones. HSDs are involved in the conversion of various steroids, including sex steroids (e.g., androgens, estrogens) and corticosteroids (e.g., cortisol, cortisone). These enzymes can be found in different tissues throughout the body, and their activity is regulated by various factors, such as hormones, growth factors, and cytokines. Dysregulation of HSDs has been implicated in several diseases, including cancer, diabetes, and cardiovascular disease.

The biliary tract is a system of ducts that transport bile from the liver to the gallbladder and then to the small intestine. Bile is a digestive fluid produced by the liver that helps in the breakdown and absorption of fats in the small intestine. The main components of the biliary tract are:

1. Intrahepatic bile ducts: These are the smaller branches of bile ducts located within the liver that collect bile from the liver cells or hepatocytes.
2. Gallbladder: A small pear-shaped organ located beneath the liver, which stores and concentrates bile received from the intrahepatic bile ducts. The gallbladder releases bile into the small intestine when food is ingested, particularly fats, to aid digestion.
3. Common hepatic duct: This is a duct that forms by the union of the right and left hepatic ducts, which carry bile from the right and left lobes of the liver, respectively.
4. Cystic duct: A short duct that connects the gallbladder to the common hepatic duct, forming the beginning of the common bile duct.
5. Common bile duct: This is a larger duct formed by the union of the common hepatic duct and the cystic duct. It carries bile from the liver and gallbladder into the small intestine.
6. Pancreatic duct: A separate duct that originates from the pancreas, a gland located near the liver and stomach. The pancreatic duct joins the common bile duct just before they both enter the duodenum, the first part of the small intestine.
7. Ampulla of Vater: This is the dilated portion where the common bile duct and the pancreatic duct join together and empty their contents into the duodenum through a shared opening called the papilla of Vater.

Disorders related to the biliary tract include gallstones, cholecystitis (inflammation of the gallbladder), bile duct stones, bile duct strictures or obstructions, and primary sclerosing cholangitis, among others.

Phenolphthalein is a chemical compound commonly used as an indicator in acid-base titrations due to its color change properties. It is colorless in acidic solutions and pink or red in basic solutions. The pH range for this color change is typically between 8.2 and 10.0, making it useful for indicating the endpoint in many titrations.

Medically, phenolphthalein has been used as a laxative to treat constipation. However, its use as a medication has largely been discontinued due to concerns about potential carcinogenic effects and other safety issues.

Cerebrotendinous xanthomatosis is a rare inherited genetic disorder that affects the metabolism of cholesterol and bile acids. It is caused by mutations in the CYP27A1 gene, which provides instructions for making an enzyme called sterol 27-hydroxylase that plays a crucial role in the conversion of cholesterol to bile acids.

As a result of this enzyme deficiency, there is an accumulation of cholesterol and its derivatives (particularly cholestanol) in various tissues and body fluids, leading to the formation of xanthomas, which are yellowish, fatty deposits that can be found under the skin, around the eyes, or in tendons.

Cerebrotendinous xanthomatosis primarily affects the nervous system, particularly the brain (cerebro-) and the tendons (-tendinous). The neurological symptoms may include chronic diarrhea, seizures, intellectual disability, ataxia (loss of balance and coordination), psychiatric disorders, and pyramidal signs (such as muscle weakness, spasticity, and hyperreflexia).

The accumulation of cholestanol in the brain can lead to progressive neurological deterioration, while the tendon xanthomas are typically found in the Achilles tendons. The diagnosis of cerebrotendinous xanthomatosis is usually confirmed through genetic testing and biochemical tests that measure the levels of cholestanol and bile acids in the blood or other body fluids.

Early diagnosis and treatment with a medication called chenodeoxycholic acid, which helps to lower cholesterol levels and reduce xanthoma formation, can significantly improve the prognosis and quality of life for individuals with cerebrotendinous xanthomatosis.

"Eubacterium" is a genus of Gram-positive, obligately anaerobic, non-sporeforming bacteria that are commonly found in the human gastrointestinal tract. These bacteria are typically rod-shaped and can be either straight or curved. They play an important role in the breakdown of complex carbohydrates and the production of short-chain fatty acids in the gut, which are beneficial for host health. Some species of Eubacterium have also been shown to have probiotic properties and may provide health benefits when consumed in appropriate quantities. However, other species can be opportunistic pathogens and cause infections under certain circumstances.

Bile canaliculi are the smallest bile-transporting structures in the liver. They are formed by the close apposition of hepatocyte (liver cell) plasma membranes, and they are responsible for the majority of bile production. The bile canaliculi merge to form bile ductules, which then merge to form larger bile ducts that transport bile to the gallbladder and small intestine. Bile is a fluid that contains water, electrolytes, bile salts, cholesterol, phospholipids, and bilirubin, which are produced by the liver and play important roles in digestion and elimination of waste products.

The gallbladder is a small, pear-shaped organ located just under the liver in the right upper quadrant of the abdomen. Its primary function is to store and concentrate bile, a digestive enzyme produced by the liver, which helps in the breakdown of fats during the digestion process. When food, particularly fatty foods, enter the stomach and small intestine, the gallbladder contracts and releases bile through the common bile duct into the duodenum, the first part of the small intestine, to aid in fat digestion.

The gallbladder is made up of three main parts: the fundus, body, and neck. It has a muscular wall that allows it to contract and release bile. Gallstones, an inflammation of the gallbladder (cholecystitis), or other gallbladder diseases can cause pain, discomfort, and potentially serious health complications if left untreated.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

"Review literature" is a term used to describe a type of scientific or academic writing that summarizes and synthesizes existing research on a particular topic. A review literature article, also known as a literature review, provides an overview of the current state of knowledge on a subject, highlighting the most important studies, methods, findings, and controversies.

A well-conducted review literature article is based on a thorough and systematic search of the relevant scientific or academic databases, journals, and other sources of information. The selection of studies for inclusion in the review is typically based on specific criteria, such as the quality of the research design, the relevance of the findings to the topic, and the publication date.

The purpose of a review literature article is to provide a critical analysis of the existing research, identify gaps in the current knowledge, and suggest directions for future research. It can also serve as a guide for researchers, clinicians, policymakers, and other stakeholders who are interested in staying up-to-date with the latest developments in their field.

In medical contexts, review literature articles are often used to inform evidence-based practice, clinical guidelines, and health policy decisions. They can also help to identify research priorities and guide funding agencies in allocating resources for future studies.

Cholangitis is a medical condition characterized by inflammation of the bile ducts, which are the tubes that carry bile from the liver to the small intestine. Bile is a digestive juice produced by the liver that helps break down fats in food.

There are two types of cholangitis: acute and chronic. Acute cholangitis is a sudden and severe infection that can cause symptoms such as abdominal pain, fever, jaundice (yellowing of the skin and eyes), and dark urine. It is usually caused by a bacterial infection that enters the bile ducts through a blockage or obstruction.

Chronic cholangitis, on the other hand, is a long-term inflammation of the bile ducts that can lead to scarring and narrowing of the ducts. This can cause symptoms such as abdominal pain, itching, and jaundice. Chronic cholangitis can be caused by various factors, including primary sclerosing cholangitis (an autoimmune disease), bile duct stones, or tumors in the bile ducts.

Treatment for cholangitis depends on the underlying cause of the condition. Antibiotics may be used to treat bacterial infections, and surgery may be necessary to remove blockages or obstructions in the bile ducts. In some cases, medications may be prescribed to manage symptoms and prevent further complications.

Liver transplantation is a surgical procedure in which a diseased or failing liver is replaced with a healthy one from a deceased donor or, less commonly, a portion of a liver from a living donor. The goal of the procedure is to restore normal liver function and improve the patient's overall health and quality of life.

Liver transplantation may be recommended for individuals with end-stage liver disease, acute liver failure, certain genetic liver disorders, or liver cancers that cannot be treated effectively with other therapies. The procedure involves complex surgery to remove the diseased liver and implant the new one, followed by a period of recovery and close medical monitoring to ensure proper function and minimize the risk of complications.

The success of liver transplantation has improved significantly in recent years due to advances in surgical techniques, immunosuppressive medications, and post-transplant care. However, it remains a major operation with significant risks and challenges, including the need for lifelong immunosuppression to prevent rejection of the new liver, as well as potential complications such as infection, bleeding, and organ failure.

While some bile acids are known to be colon tumor promoters (e.g. deoxycholic acid), others such as ursodeoxycholic acid are ... Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ (March 2018). "The bile acids, deoxycholic acid and ursodeoxycholic acid, ... ursodeoxycholic acid can be toxic. Ursodeoxycholic acid has been shown to exert anti-inflammatory and protective effects in ... "Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic ...
Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ (March 2018). "The bile acids, deoxycholic acid and ursodeoxycholic acid, ... The active ingredient in bear bile is ursodeoxycholic acid. Ursodeoxycholic acid has been shown to exert anti-inflammatory and ... "Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic ... Huang, Xiaomei (2015). "Preparation of ursodeoxycholic acid from 7-ketone lithocholic acid by stereoselective electroreduction ...
... but some researchers believe that it may still be useful to offer ursodeoxycholic acid to women whose bile acids are > 40 μmol/ ... Many providers will prescribe ursodeoxycholic acid. The most recent trial, PITCHES, did not show an overall beneficial effect, ... 1995). "Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid ... "Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve ...
The first-line treatment for PBC is ursodeoxycholic acid (UDCA). UDCA has been the only drug available for two decades and more ... Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (December 2012). "Ursodeoxycholic acid for primary biliary cirrhosis". ... September 2018). "Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and ... Anion-exchange resins relieve itching caused by excess bile acids in circulation by binding bile acids in the gut and ...
Ursodeoxycholic acid Hyodeoxycholic acid Russell DW (2003). "The enzymes, regulation, and genetics of bile acid synthesis". ... Chenodeoxycholic acid (CDCA; also known as chenodesoxycholic acid, chenocholic acid and 3α,7α-dihydroxy-5β-cholan-24-oic acid) ... lithocholic acid or the epimer, ursodeoxycholic acid. CDCA is the most potent natural bile acid at stimulating the nuclear bile ... Chenodeoxycholic acid and cholic acid are the two primary bile acids in humans. Chenodeoxycholic acid has two hydroxyl groups ...
Ursodeoxycholic acid, a bile salt, has been used; however, there is insufficient data to show if it is effective. It is ... Cheng K, Ashby D, Smyth RL (September 2017). "Ursodeoxycholic acid for cystic fibrosis-related liver disease". The Cochrane ... In some cases, they can cause the cell to overcome a premature stop codon by inserting a random amino acid, thereby allowing ... These drugs target nonsense mutations such as G542X, which consists of the amino acid glycine in position 542 being replaced by ...
Some medication, such as ursodeoxycholic acid, may be used; lithotripsy, a non-invasive mechanical procedure used to break down ...
Cheng, Katharine; Ashby, Deborah; Smyth, Rosalind L. (2017). "Ursodeoxycholic acid for liver disease related to cystic fibrosis ... Obese mice also have higher levels of deoxycholic acid, a product of bile acid alteration by certain gut microbes, and these ... a medication called ursodeoxycholic acid may be given. Model for end-stage liver disease (MELD) "Liver Diseases". MedlinePlus. ... The excess deoxycholic acid causes DNA damage and inflammation in the liver, which, in turn, can lead to liver cancer. Several ...
In the treatment of ICP, current evidence suggests ursodeoxycholic acid (UDCA), a minor secondary bile acid in humans, is the ... Dumont M, Erlinger S, Uchman S (July 1980). "Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the ... February 2017). "Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing ... The primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA) are synthesized in the liver and undergo conjugation ...
There are additional secondary bile acids, such as ursodeoxycholic acid. Deoxycholic acid is soluble in alcohol and acetic acid ... Deoxycholic acid is a bile acid. Deoxycholic acid is one of the secondary bile acids, which are metabolic byproducts of ... Bacteria metabolize chenodeoxycholic acid into the secondary bile acid lithocholic acid, and they metabolize cholic acid into ... September 2009). "Consumption of some polyphenols reduces fecal deoxycholic acid and lithocholic acid, the secondary bile acids ...
... oral ursodeoxycholic acid can alleviate the condition. A trial of bile acid sequestrant therapy is recommended for bile acid ... Okoro N, Patel A, Goldstein M, Narahari N, Cai Q (July 2008). "Ursodeoxycholic acid treatment for patients with ... Chronic diarrhea in postcholecystectomy syndrome is a type of bile acid diarrhea (type 3). This can be treated with a bile acid ... Sciarretta G, Furno A, Mazzoni M, Malaguti P (December 1992). "Post-cholecystectomy diarrhea: evidence of bile acid ...
Some experts recommend a trial of ursodeoxycholic acid (UDCA), a bile acid occurring naturally in small quantities in humans, ... Tabibian JH, Lindor KD (September 2014). "Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then ... September 2009). "High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis". Hepatology. 50 (3): 808- ... Obeticholic acid is being investigated as a possible treatment for PSC due to its antifibrotic effects. Simtuzumab is a ...
February 2005). "Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis". Alimentary ... There is increased expression of the 'endothelin axis' consisting of 21 amino acid peptides (ET-1, ET-2 and ET-3), two GPCRs ... differing only in two amino acids (with Trp6 and Leu7 instead of Leu6 and Met7) it was often assumed that the two endothelins ...
... such as chenodeoxycholic acid and ursodeoxycholic acid. On an empty stomach - after repeated vomiting, for example - a person's ... Cholic acid Chenodeoxycholic acid Glycocholic acid Taurocholic acid Deoxycholic acid Lithocholic acid Medicine portal Animals ... "Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed". World Journal of Gastroenterology. 19 (31): ... As an alkali, it also has the function of neutralizing excess stomach acid before it enters the duodenum, the first section of ...
Biliary sludge Okoro, Ngozi; Patel, Amil; Goldstein, Marney; Narahari, Naveen; Cai, Qiang (Jul 2008). "Ursodeoxycholic acid ... "Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis". Gastrointest Endosc. 68 (1 ... Oral ursodeoxycholic acid can be used to dissolve these crystals. ...
Several drugs are used off label by patients with EPP: Ursodeoxycholic acid is a bile acid that is administered to promote ... Paumgartner G, Beuers U (September 2002). "Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and ... improvement of liver function with ursodeoxycholic acid". The American Journal of Gastroenterology. 96 (12): 3468-3469. doi: ... Screening for FECH mutation on one allele or aminolevulinic acid synthase 2 gain-of-function mutation in selected family ...
The medications ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) have been used in treatment to dissolve gallstones ... Ursodeoxycholic acid (UDCA) appears to prevent formation of gallstones during weight loss. A high fat diet during weight loss ... Stokes CS, Gluud LL, Casper M, Lammert F (July 2014). "Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones ... Bile acid malabsorption may also be a risk. Cholesterol gallstones develop when bile contains too much cholesterol and not ...
Treatment with ursodeoxycholic acid has been used for many years in these cholestatic disorders. The relationship of bile acids ... bile acids Cholic acid Glycocholic acid Taurocholic acid Deoxycholic acid Chenodeoxycholic acid Glycochenodeoxycholic acid ... Cholic acid is converted into deoxycholic acid and chenodeoxycholic acid into lithocholic acid. All four of these bile acids ... Conjugating bile acids with amino acids lowers the pKa of the bile-acid/amino-acid conjugate to between 1 and 4. Thus ...
Ursodeoxycholic acid has been used successfully as a treatment for cases with liver involvement. Thalidomide has also been ... Almenoff PL, Johnson A, Lesser M, Mattman LH (May 1996). "Growth of acid fast L forms from the blood of patients with ... Due to these safety concerns it is often recommended that methotrexate is combined with folic acid in order to prevent toxicity ... Mycophenolic acid has been used successfully in uveal sarcoidosis, neurosarcoidosis (especially CNS sarcoidosis; minimally ...
Ursodeoxycholic acid and tauroursodeoxycholic acid were first chemically synthesized in 1954 in Japan. Ursodeoxycholic acid is ... Bear bile contains several bile acids including taurochenodeoxycholic acid, ursodeoxycholic acid, and chenodeoxycholic acid. ... Woo SJ, Kim JH, Yu HG (2010). "Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a ... acid is a naturally occurring hydrophilic bile acid which is the taurine conjugated form of ursodeoxycholic acid (UDCA). Humans ...
This produces α-muricholic acid from chenodeoxycholic acid, and β-muricholic acid from ursodeoxycholic acid. Tauromuricholic ... α-muricholic acid β-muricholic acid γ-muricholic acid (hyocholic acid) ω-muricholic acid Russell DW (2003). "The enzymes, ... Muricholic acids differ from the primary bile acids found in humans, cholic acid and chenodeoxycholic acid, by having a ... The three major bile acids in germ-free mice are cholic acid, α-muricholic, and β-muricholic acids. In conventional mice with a ...
In primary biliary cirrhosis, ursodeoxycholic acid helps the bloodstream remove bile, which may increase survival. ...
"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid". ... Ursodeoxycholic acid therapy is beneficial, but the disease often progresses and may require liver transplantation. Animal ... It is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an ... Obeticholic acid (OCA), sold under the brand name Ocaliva, is a semi-synthetic bile acid analogue which has the chemical ...
Besides, ursodeoxycholic acid and probiotic VSL#3 may stimulate the expression of ENPP7 in the intestine. GRCh38: Ensembl ... Liu F, Cheng Y, Wu J, Tauschel HD, Duan RD (April 2006). "Ursodeoxycholic acid differentially affects three types of ... Unlike acid and neutral SMases in the intestinal tract that are rapidly inactivated by pancreatic trypsin, alk-SMase is ... created based on the results of cloning studies which show that alk-SMase shares no structural similarities with either acid or ...
"Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial". ... "Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging ...
Ursodeoxycholic acid (UDCA), by upregulating the corepressor small heterodimer partner interacting leucine zipper protein ( ... "Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional ... SMRT (silencing mediator of retinoic acid and thyroid hormone receptor), also known as NCoR2, is an alternatively spliced SRC-1 ... Nucleic Acids Res. 39 (Database issue): D106-10. doi:10.1093/nar/gkq945. PMC 3013796. PMID 20965969. Bolander, Franklyn F. ( ...
Antibiotics are used to treat the inflammation of the bile duct, and ursodeoxycholic acid is used for hepatolithiasis. Ursodiol ...
In a study evaluating the effects on ursodeoxycholic acid (UDCA) on bile flow and cirrhosis, NO was found in bile as SNOs, ... "Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat ...
Bile reflux is usually associated with: Erosive esophagitis Barrett's esophagus Ursodeoxycholic acid is an adequate treatment ... acid reflux is backflow of stomach acid into the esophagus. These conditions are often related, and differentiating between the ... Biliary reflux can be confused with acid reflux, also known as gastroesophageal reflux disease (GERD). While bile reflux ... Distinguishing Between Bile Reflux and Acid Reflux can be Difficult Mabrut JY, Collard JM, Baulieux J (2006). "[Duodenogastric ...
... and ursodeoxycholic acid. These drugs have been tested in individual patients with fibrin storage disease with some success in ... Incomplete response to carbamazepine and ursodeoxycholic acid". BMC Gastroenterology. 16 (1): 92. doi:10.1186/s12876-016-0507-3 ... Tranexamic acid may be used in place of fibrinogen supplementation as prophylactic treatment prior to minor surgery and to ... of the amino acid changed by the mutation in the circulating peptide of the mutated fibrinogen, and the identity of the amino ...
While some bile acids are known to be colon tumor promoters (e.g. deoxycholic acid), others such as ursodeoxycholic acid are ... Mroz MS, Lajczak NK, Goggins BJ, Keely S, Keely SJ (March 2018). "The bile acids, deoxycholic acid and ursodeoxycholic acid, ... ursodeoxycholic acid can be toxic. Ursodeoxycholic acid has been shown to exert anti-inflammatory and protective effects in ... "Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic ...
APO-URSODEOXYCHOLIC ACIDContains the active ingredient ursodeoxycholic acidConsumer Medicine InformationFor a copy of a large ... The dose for ursodeoxycholic acid is determined by your body weight. Your doctor should tell you how much ursodeoxycholic acid ... The name of your medicine is APO-Ursodeoxycholic Acid Capsules. It contains the active ingredient ursodeoxycholic acid. ... Ursodeoxycholic acid is a bile acid, which may have a protective effect on the liver by reducing the absorption of other ...
... Review publications at Sutter Health. ... Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary ... BACKGROUND: We used data from the Fibrotic Liver Disease Consortium to evaluate the impact of ursodeoxycholic acid (UDCA) ...
Preliminary data suggest that ursodeoxycholic acid (UDCA) may be beneficial for treatment of this manifestation. We performed a ... The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis Hepatology. 1996 Jun;23(6):1484-90. doi: 10.1002/hep ... Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. ... Preliminary data suggest that ursodeoxycholic acid (UDCA) may be beneficial for treatment of this manifestation. We performed a ...
Effect of Ursodeoxycholic Acid (UDCA) on Primary Bile Acid Kinetics in Gallstone Patients G. Williams; G. Williams ... G. Williams, L. Mathews, N. F. Breuer, G. M. Murphy, R. H. Dowling; Effect of Ursodeoxycholic Acid (UDCA) on Primary Bile Acid ...
Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review ... Developing a procedure to extract chenodeoxycholic acid and synthesize ursodeoxycholic acid from pig by-products. Heliyon 2023, ... Kollerov, V.; Donova, M. Ursodeoxycholic acid production by Gibberella zeae mutants. AMB Express 2022, 12, 105. doi:10.1186/ ... Song, P.; Zhang, X.; Feng, W.; Xu, W.; Wu, C.; Xie, S.; Yu, S.; Fu, R. Biological synthesis of ursodeoxycholic acid. Frontiers ...
Because in vitro and in vivo studies suggest that the more hydrophilic bile acid tauroursodeoxycholate has greater beneficial ... Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with ... Fecal bile acid excretion was the major route of elimination of both bile acids; ursodeoxycholate accounted for 8% and 23% of ... Bile acids were measured in serum, duodenal bile, urine, and feces by gas chromatography-mass spectrometry (GC-MS). Biliary ...
global ursodeoxycholic acid API market size was USD 488.7 million in 2022 and is expected to reach USD 954.2 million in 2028, ... What value is the global ursodeoxycholic acid API market expected to touch by 2028? The global ursodeoxycholic acid API market ... What CAGR is the ursodeoxycholic acid API market expected to exhibit during 2022-2028? The ursodeoxycholic acid API market is ... Bile acids such as ursodeoxycholic acid API have been shown to combine with taurine in the bile of bears (Ursidae). When used ...
A publicly available article also appearing in PubMed about Ursodeoxycholic Acid ... Ljubuncic P,Fuhrman B,Oiknine J,Aviram M,Bomzon A, Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in ... Therapeutic concentrations of ursodeoxycholic acid can shift the concentration of bile acids from hydrophobicity to ... It becomes oxidized or reduced, yielding either 7-keto-lithocholic acid or lithocholic acid. Litcholic acid can be toxic to ...
Gallstones are made up of pure cholesterol (80% of cases) or a mixture of cholesterol/calcium/bile salts. Nearly 15% of adults have gallstones that will.... ...
URSODEOXYCHOLIC ACID 150MG TABLET, BRAND NAME: MELIV-150, PACKAGING TYPE: ALU/ALU, PACKING: 10*10, AVAILABLE IN THE BEST ...
ursodiol (ursodeoxycholic acid) Nursing Considerations & Management Drug Name. Generic Name : ursodiol (ursodeoxycholic acid) ...
Texas Pharmaceuticals a Leading Manufacturers & Suppliers of High Quality cGMP Medication promoting through PCD Pharma, Pharma Franchise in India. We are an ISO 9001:2015 Certified Pharmaceutical Company earned Quality Excellence award through our constant endeavour to produce low price high quality products. ...
ICE Pharma are experts in the development and manufacture of bile acid derivatives and are a leading producer of ... We have a unique range of bile acid products and are a leading global integrated producer of Ursodeoxycholic acid (UDCA).. View ... We have a unique range of bile acid products and are a leading global integrated producer of Ursodeoxycholic acid (UDCA). ... We are a leading producer of Ursodeoxycholic Acid (UDCA) with an integrated global manufacturing network in Europe, Latin ...
Ursodeoxycholic Acid 300 Mg Manufacturer in Haryana. We are Indias leading quality Ursodeoxycholic Acid 300 Mg supplier and ... Ursodeoxycholic Acid 300 Mg Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), ...
... , Brand Name: URSORIV 300, available at EAR India ...
... should ursodeoxycholic acid be considered to help dissolve the stones and reduce the risk of biliary disease? ... In patients in whom cholelithiasis with numerous stones is incidentally noted on imaging, should ursodeoxycholic acid be ... In patients in whom cholelithiasis with numerous stones is incidentally noted on imaging, ursodeoxycholic acid (ursodiol) ... In Cholelithiasis, What Role for Ursodeoxycholic Acid Rx?. August 14, 2013. Article ...
... is a secondary bile acid found in small quantities in human bile. ... Ursodeoxycholic Acid(CAS No.128-13-2), also known as UDCA or ... What is Ursodeoxycholic Acid?. Ursodeoxycholic Acid, also known as UDCA or ursodiol, is a secondary bile acid found in small ... PRODUCT NAME:Ursodeoxycholic acid. Discover the therapeutic wonders of Ursodeoxycholic Acid (UDCA), a remarkable medication ... How Does Ursodeoxycholic Acid Work?. UDCAs mechanism of action revolves around its dual benefits for liver health. Firstly, it ...
Ursodeoxycholic Acid EP Impurity B. Request a quote now. ... Ursodeoxycholic Acid EP Impurity B. Ursodeoxycholic Acid EP ... Ursodeoxycholic Acid EP Impurity B is an impurity of Ursodeoxycholic Acid, Ursodeoxycholic Acid is an important clinical drug ... Sci-Hub, Preparation of ursodeoxycholic acid from 7-ketone lithocholic acid by stereoselective electroreduction, 10.1186/s40643 ... Sci-Hub, Preparation of ursodeoxycholic acid from 7-ketone lithocholic acid by stereoselective electroreduction, 10.1186/s40643 ...
Ursodeoxycholic Acid and Silymarin Tablets, Ursodeoxycholic Acid Tablets IP offered by Cista Medicorp, Panchkula, Haryana. ... Offering you a complete choice of products which include ursodeoxycholic acid and silymarin tablets and ursodeoxycholic acid ... We are the leading and prominent Manufacturer and Supplier of Ursodeoxycholic Acid and Silymarin Tablets. ... We are the leading and prominent Manufacturer and Supplier of Ursodeoxycholic Acid Tablets IP. ...
Ursodeoxycholic acid (3?, 7?-2-hydroxy-5?-bile acid, UDCA) was first found in the bile of a bla... ... Ursodeoxycholic Acid is also known as ursodiol (USAN). ... Chapter 4 China Ursodeoxycholic Acid API Market, by Type * 4.1 ... Ursodeoxycholic Acid is also known as ursodiol (USAN). Ursodeoxycholic acid (3?, 7?-2-hydroxy-5?-bile acid, UDCA) was first ... Chapter 6 China Ursodeoxycholic Acid API Market, by Region * 6.1 China Ursodeoxycholic Acid API Production Volume and ...
Ursodeoxycholic Acid 300 Mg Tablet, Ursodeoxycholic Acid 150mg Tablet, Rifaximin 400mg (Color Sunset yellow and titanium ... Our product range includes a wide range of ursodeoxycholic acid 300 mg tablet, ursodeoxycholic acid 150mg tablet, rifaximin ... Ursodeoxycholic Acid Tablets 150mg are indicated for the dissolution of radiolucent cholesterol-rich gallstones in adults, ... Methylcobalamine 1500mcg Alpha Lipoic Acid 100 mg Vitamin B1 10mg Vitamin B6 3 mg Folic Acid ...
Ursodeoxycholic Acid Tablets IP, Ayurvedic Memory Booster Syrup, Herbal Liver Tonic PCD Pharma and Ayurvedic Utrine Tonic ... Offering you a complete choice of products which include ursodeoxycholic acid tablets ip, ayurvedic memory booster syrup, ...
Suzhou Jingye Medicine & Chemical Co., Ltd., a national high-tech enterprise, is located in the Suzhou High-tech Industrial Development Zone, about 100 kilometers away from Shanghai.
Get the best deals for URSOLIN Ursolin Ursodeoxycholic acid 250mg 1 capsule [Prescription Required]. ... Buy Ursolin Ursodeoxycholic acid 250mg 1 capsule [Prescription Required] online at Watsons Philippines. ... Each capsule contains 250mg Ursodeoxycholic acid. Storage Information Store below 25°C in a dry place, away from direct ...
... with routine use of second-line therapy in nonresponders to first-line therapy with ursodeoxycholic acid (UDCA). The mechanism ... with routine use of second-line therapy in nonresponders to first-line therapy with ursodeoxycholic acid (UDCA). The mechanism ...
... especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal ... especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal ... especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal ... especially secondary bile acids, and colorectal cancer. Ursodeoxycholic acid, a synthetic bile acid, has been shown in animal ...
We use cookies to ensure that we give you the best experience on our website. If you click Accept all cookies well assume that you are happy to receive all cookies and you wont see this message again. If you click Reject all non-essential cookies only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click Find out more for information on how to change your cookie settings. ...
All posts tagged: Ursodeoxycholic Acid Tablet supplier Third Party Manufacturing , PCD Pharma Franchise , Casca Remedies. , ...
Ursodeoxycholic Acid from Loyal Bio-Chemical Manufacture Co.,Ltd,Ursodeoxycholic Acid Distributor online Service suppliers. ... About Ursodeoxycholic Acid Ursodeoxycholic acid is white powder,almost insoluble in water,freely soluble in alcohol ... Ursodiol Active Pharmaceutical Ingredients Ursodeoxycholic Acid. *. Animal Extracts Pharmaceutical Raw Powder Ursodeoxycholic ... Ursodeoxycholic acid (UDCA), also known as ursodiol, is a compound produced from bile by the action of intestinal bacteria. ...
  • Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal bacteria. (wikipedia.org)
  • Diarrhea was the most frequent adverse event seen in trial of UDCA in gallstone dissolution, occurring in 2 to 9%, which is less frequent than with chenodeoxycholic acid therapy. (wikipedia.org)
  • Bacterial conversion of UDCA to chenodeoxycholic acid may be the mechanism for this side effect. (wikipedia.org)
  • BACKGROUND: We used data from the Fibrotic Liver Disease Consortium to evaluate the impact of ursodeoxycholic acid (UDCA) treatment across race/ethnicity, gender, and clinical status among patients with primary biliary cholangitis. (sutterhealth.org)
  • Liver disease is increasingly recognized as a major cause of morbidity in cystic fibrosis (CF). Preliminary data suggest that ursodeoxycholic acid (UDCA) may be beneficial for treatment of this manifestation. (nih.gov)
  • We have a unique range of bile acid products and are a leading global integrated producer of Ursodeoxycholic acid (UDCA). (icepharma.com)
  • We are a leading producer of Ursodeoxycholic Acid (UDCA) with an integrated global manufacturing network in Europe, Latin America, Asia and Oceania that serves customers in over 50 countries. (icepharma.com)
  • Discover the therapeutic wonders of Ursodeoxycholic Acid (UDCA), a remarkable medication known for its efficacy in promoting liver health and managing various hepatobiliary conditions. (arshinepharma.com)
  • Ursodeoxycholic Acid, also known as UDCA or ursodiol, is a secondary bile acid found in small quantities in human bile. (arshinepharma.com)
  • bile acid, UDCA) was first found in the bile of a black bear. (globalmarketmonitor.com)
  • BACKGROUND AND AIMS: Stratified therapy has entered clinical practice in primary biliary cholangitis (PBC), with routine use of second-line therapy in nonresponders to first-line therapy with ursodeoxycholic acid (UDCA). (cam.ac.uk)
  • Some studies suggest that ursodeoxycholic may reduce the colorectal cancer risk, but to date the studies are small, mostly retrospective, and lacking in solid evidence to support use of UDCA for colorectal cancer chemoprophylaxis. (elsevierpure.com)
  • About Ursodeoxycholic Acid Ursodeoxycholic acid is white powder,almost insoluble in water,freely soluble in alcohol Ursodeoxycholic acid (UDCA), also known as ursodiol, is a compound produced from bile by the action of intestinal bacteria. (shangyishiye.com)
  • IntraBio Inc today announced that the US Food and Drug Administration has granted Orphan Drug Designation to Ursodeoxycholic Acid (UDCA) for the treatment of Niemann-Pick disease type C. (intrabio.com)
  • IntraBio Ltd, a clinical stage biopharmacuetical company developing treatments for rare lysosomal storage disorders and neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation (EU/3/17/1878) to Ursodeoxycholic Acid (UDCA) for the treatment of Niemann-Pick disease (NPC) Type A, B, and C. (intrabio.com)
  • BACKGROUND & AIMS: Ursodeoxycholic acid (UDCA) is used for the treatment of cholestatic liver diseases including primary biliary cirrhosis (PBC) for which it has a positive effect on laboratory values, may delay the development of liver failure and prolong the transplant-free disease period. (ox.ac.uk)
  • Purity: 99% Storage: Sealed, light and oxygen resistant Packing:25kg/drum or as required Description : Ursodeoxycholic Acid is white powder,almost insoluble in water,freely soluble in alcohol Ursodeoxycholic acid (UDCA), also known as ursodiol, is a compound produced from bile by the action of intestinal bacteria. (toextrade.com)
  • Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive applications in nutraceutical and pharmaceutical products. (dalgonamagazine.com)
  • In this context, we aimed to combine the anti-inflammatory properties of geraniol (GER) with the mitochondrial rescue effects of ursodeoxycholic acid (UDCA) in a newly-synthesized prodrug, GER-UDCA, a potential candidate against Parkinson's disease (PD). (unimore.it)
  • Background Ursodeoxycholic acid (UDCA) and obeticholic acid are currently approved treatments for primary biliary cholangitis (PBC). (annalsgastro.gr)
  • We investigated the in vitro effects on cell proliferation, apoptosis, and COX-2 expression of the potential chemopreventives celecoxib and tauro-ursodeoxycholic acid (UDCA). (fapvoice.com)
  • HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA. (fapvoice.com)
  • Background & Aims: Outcomes in primary biliary cirrhosis (PBC) can be predicted by biochemical response to ursodeoxycholic acid (UDCA). (eur.nl)
  • Since therapy with colestyramin, antihistaminics, naloxon and ursodeoxycholic acid (UDCA) did not improve symptoms, we decided to perform plasma absorption and to start rifampicin therapy. (elsevier.es)
  • Ursodiol and obeticholic acid are FDA-approved for the treatment of primary biliary cholangitis. (wikipedia.org)
  • A naturally occurring bile acid called ursodeoxycholic acid, also known as ursodiol, is used to dissolve cholesterol gallstones and treat cholestatic liver disorders, such as primary biliary cirrhosis. (businessresearchinsights.com)
  • Ursodeoxycholic Acid is also known as ursodiol (USAN). (globalmarketmonitor.com)
  • Ursodiol is a bile acid, a natural substance produced by the liver. (rxwiki.com)
  • Ursodeoxycholic acid treatment for biliary cholangitis. (sutterhealth.org)
  • Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis. (sutterhealth.org)
  • The market for ursodeoxycholic acid API is anticipated to expand as liver-related illnesses such cholestasis, primary biliary cholangitis (PBC), and non-alcoholic fatty liver disease (NAFLD) become more common. (businessresearchinsights.com)
  • The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. (cam.ac.uk)
  • Ursodeoxycholic acid is produced in several countries for the treatment of gallstones and primary biliary cholangitis. (tauroursodeoxycholic.com)
  • Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid. (ox.ac.uk)
  • A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. (ox.ac.uk)
  • PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched in order to find randomized controlled trials evaluating the effect of ursodeoxycholic acid on lipid profile. (biomedcentral.com)
  • Evidence suggests that the therapeutic effects of ursodeoxycholic acid are explained by an increased hydrophilicity index of the bile acid pool, stimulation of hepatocellular and ductular secretions, cytoprotection against bile acid and cytokine-induced injury, immunomodulation and anti-inflammatory effects [ 17 ]. (biomedcentral.com)
  • Xu, J.-H. Clean enzymatic production of ursodeoxycholic acid enabled by a newly identified NADH-dependent 7β-hydroxysteroid dehydrogenase. (beilstein-journals.org)
  • Hur, S. J. Developing a procedure to extract chenodeoxycholic acid and synthesize ursodeoxycholic acid from pig by-products. (beilstein-journals.org)
  • However, sphincterotomy alters emptying dynamics of the gallbladder and markedly reduces bile salt pool size, effects that may alter response to chenodeoxycholic acid or ursodeoxycholic acid treatment. (umn.edu)
  • These findings suggest a defect in biliary excretion, particularly of chenodeoxycholic acid conjugates. (medscape.com)
  • Wu, Y. Development of HPLC-CAD method for simultaneous quantification of nine related substances in ursodeoxycholic acid and identification of two unknown impurities by HPLC-Q-TOF-MS. Journal of pharmaceutical and biomedical analysis 2023, 229, 115357. (beilstein-journals.org)
  • For therapy of chronic cholestatic liver disorders, ursodeoxycholic acid API is being used more and more. (businessresearchinsights.com)
  • Ursodeoxycholic acid is widely prescribed in the treatment of several cholestatic liver diseases such as cholesterol-gallstone dissolution, primary biliary cirrhosis and cholestasis of pregnancy [ 16 , 17 ]. (biomedcentral.com)
  • 05). Lithocholic acid concentration was consistently higher in all biological fluids during ursodeoxycholate administration. (nih.gov)
  • Sci-Hub, Preparation of ursodeoxycholic acid from 7-ketone lithocholic acid by stereoselective electroreduction, 10.1186/s40643-015-0058-4. (veeprho.com)
  • Agilent is investing $725m to double its therapeutic nucleic acids manufacturing capacity in Frederick, Colorado, by 2026. (pharmaceutical-technology.com)
  • When secreted into the intestine, primary bile acids can be metabolized into secondary bile acids by intestinal bacteria. (wikipedia.org)
  • Primary and secondary bile acids help the body digest fats. (wikipedia.org)
  • Animal and human data suggest a relationship between bile acids, especially secondary bile acids, and colorectal cancer. (elsevierpure.com)
  • Our product range includes a wide range of ursodeoxycholic acid 300 mg tablet, ursodeoxycholic acid 150mg tablet, rifaximin 400mg (color sunset yellow and titanium dioxide) tablet, povidone iodine germicide gargle 2 wv, torsemide 20mg tablet and silodosin 8mg + dutasteride 0.5mg capsule. (sanifyhealthcare.co.in)
  • Offering you a complete choice of products which include ursodeoxycholic acid and silymarin tablets and ursodeoxycholic acid tablets ip. (cistamedicorp.in)
  • These compounds include human, animal species and synthetic bile acids, their salts and amino acid conjugates. (icepharma.com)
  • Since this bile acid is not produced directly by the body, it is known as a secondary bile acid.One of the functions of bile acids is to act in the intestine to help digest fats and fatsoluble vitamins from food. (toextrade.com)
  • Offering you a complete choice of products which include ursodeoxycholic acid tablets ip, ayurvedic memory booster syrup, herbal liver tonic pcd pharma and ayurvedic utrine tonic. (edmundhealthcare.in)
  • Primary bile acids are produced by the liver and stored in the gall bladder. (wikipedia.org)
  • Ursodeoxycholic acid is a primary bile acid formed in the human liver [ 13 , 14 ]. (biomedcentral.com)
  • It contains the active ingredient ursodeoxycholic acid. (mydr.com.au)
  • The primary driver propelling expansion of the worldwide ursodeoxycholic API sector during the forecast period is the rise in the prevalence of gallstones and cystic fibrosis. (businessresearchinsights.com)
  • Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients. (kritipcdpharma.com)
  • Gallstone Management: Ursodeoxycholic Acid is effective in dissolving small cholesterol gallstones, reducing the need for surgical interventions and facilitating a safer, non-invasive approach to gallstone management. (arshinepharma.com)
  • The aim of this meta-analysis of randomized placebo-controlled trials was to examine whether ursodeoxycholic acid treatment is an effective lipid-lowering agent. (biomedcentral.com)
  • Therefore, the present meta-analysis of randomized placebo-controlled trials aimed to examine whether ursodeoxycholic acid treatment is an effective lipid-lowering agent. (biomedcentral.com)
  • Moreover, it serves as a crucial intermediate compound for tauroursodeoxycholic acid (TUDCA), an essential active pharmaceutical ingredient in a recently approved combination therapy for the treatment of ALS in Canada and the United States. (dalgonamagazine.com)
  • In Cholelithiasis, What Role for Ursodeoxycholic Acid Rx? (patientcareonline.com)
  • In patients in whom cholelithiasis with numerous stones is incidentally noted on imaging, should ursodeoxycholic acid be considered to help dissolve the stones and reduce the risk of biliary disease? (patientcareonline.com)
  • ICE Pharma is an expert in the development and manufacture of bile acid derivatives. (icepharma.com)
  • Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. (nih.gov)
  • Ursodeoxycholic Acid EP Impurity B (CAS No: 81-25-4) Or 3a,7a,12a-Trihydroxy-5v-cholan-24-oic acid, Ursodeoxycholic Acid EP Impurity B is an impurity of Ursodeoxycholic Acid, Ursodeoxycholic Acid is an important clinical drug in the treatment of liver disease, which is s prepared by traditional organic synthesis. (veeprho.com)
  • Because in vitro and in vivo studies suggest that the more hydrophilic bile acid tauroursodeoxycholate has greater beneficial effects than ursodeoxycholate, we have compared for the first time the absorption, metabolism, and clinical responses to these bile acids in patients with primary biliary cirrhosis (PBC). (nih.gov)
  • Bile acids such as ursodeoxycholic acid API have been shown to combine with taurine in the bile of bears (Ursidae). (businessresearchinsights.com)
  • You are hypersensitive to, or have had an allergic reaction to, ursodeoxycholic cid or any of the ingredients listed at the end of this leaflet. (mydr.com.au)
  • 3alpha, 7beta-dioxycholanic acid Cas: 128-13-2 Mf: C24h40o4 Mw: 392.57 Einecs: 204-879-3 Appearance: White or almost white powder Application: For the prevention treatment of choles. (toextrade.com)
  • This conclusion is supported by the differences in the quantitative and qualitative distribution of bile acids in serum and bile. (medscape.com)
  • Fu, R. Biological synthesis of ursodeoxycholic acid. (beilstein-journals.org)
  • Possible mechanisms for steatosis include reduced synthesis of very low density lipoprotein (VLDL) and increased hepatic triglyceride synthesis (possibly due to decreased oxidation of fatty acids or increased free fatty acids being delivered to the liver). (merckmanuals.com)
  • Carey, EJ & Lindor, K 2012, ' Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons ', Clinics and Research in Hepatology and Gastroenterology , vol. 36, no. (elsevierpure.com)
  • sodium phenylbutyrate and ursodeoxycholic acid. (medscape.com)
  • 20 mmol/L) and have a predominance of cholic acid conjugates. (medscape.com)
  • Ursodeoxycholic acid helps regulate cholesterol by reducing the rate at which the intestine absorbs cholesterol molecules while breaking up micelles containing cholesterol. (wikipedia.org)
  • In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. (hindawi.com)
  • A long-term trial of bile acid treatment in sphincterotomy patients with stones in an intact gallbladder is needed. (umn.edu)
  • Celecoxib and Tauro-Ursodeoxycholic Acid Co-Treatment Inhibits Cell Growth in Familial Adenomatous Polyposis Derived LT97 Colon Adenoma Cells. (fapvoice.com)
  • Ursodeoxycholic acid is a bile acid, which may have a protective effect on the liver by reducing the absorption of other potentially toxic bile salts. (mydr.com.au)
  • Wang, J.-S. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children. (beilstein-journals.org)
  • The mechanism whereby the loss of FIC1 activity results in defective bile salts excretion is unknown, but it has been hypothesized that a mutation in this protein causes phospholipid membrane instability leading to reduced function of bile acid transporters. (medscape.com)
  • Verma, A. , Jazrawi, R.P. , Ahmed, H.A. and Northfield, T.C. (2000) The optimum dose of ursodeoxycholic acid in primary biliary cirrhosis. (kingston.ac.uk)
  • Ursodeoxycholic acid has been shown to exert anti-inflammatory and protective effects in human epithelial cells of the gastrointestinal tract. (wikipedia.org)
  • This meta-analysis suggests that ursodeoxycholic acid therapy might be associated with significant total cholesterol lowering particularly in patients with primary biliary cirrhosis. (biomedcentral.com)
  • While some bile acids are known to be colon tumor promoters (e.g. deoxycholic acid), others such as ursodeoxycholic acid are thought to be chemopreventive, perhaps by inducing cellular differentiation and/or cellular senescence in colon epithelial cells. (wikipedia.org)
  • Evidence is accumulating that ursodeoxycholic acid is ineffective, unsafe and its use is associated with significant risk of morbidity and mortality in neonatal hepatitis and neonatal cholestasis. (wikipedia.org)